6 results match your criteria: "Department of Gastroenterology Yokohama City University Graduate School of Medicine Yokohama Japan.[Affiliation]"
Article Synopsis
- - This study aimed to compare the effectiveness of two first-line treatments for Helicobacter pylori eradication: a triple therapy featuring vonoprazan, amoxicillin, and metronidazole (VAM) versus another using vonoprazan, amoxicillin, and clarithromycin (VAC).
- - Conducted in Japan with 124 participants, the trial showed that both treatments yielded similar success rates for eradication, around 91% for VAM and 89% for VAC, without significant differences between them.
- - The results indicate that VAM can be considered an effective first-line treatment and suggests its classification as a grade B regimen, indicating a good potential for national insurance approval in Japan.
Background And Aim: The incidence of metachronous gastric cancer (MGC) after endoscopic treatment for early gastric cancer (EGC) is high, but a method of risk assessment for MGC based on endoscopic findings has not been established. In this study, we focused on endoscopic intestinal metaplasia (IM) and investigated the risk for MGC after endoscopic submucosal dissection (ESD) for EGC.
Methods: This retrospective observational study involved patients who underwent curative ESD for EGC from April 2015 to January 2021.
Background: To date, no interventional trial has assessed the efficacy and safety of vonoprazan and high-dose (500 mg four times daily, 2000 mg/day) amoxicillin dual therapy in terms of eradication. We explored whether this was an appropriate first-line treatment.
Methods: This prospective, dual-center, single-arm interventional study was performed in Japan.
Background And Aim: To assess the efficacy and safety of 7-day rescue treatment consisting of a vonoprazan (VPZ), metronidazole (MNZ), and sitafloxacin (STFX) regimen (VPZ-MNZ-STFX therapy) in patients with penicillin allergy.
Methods: This was a registered prospective intervention study. Patients with penicillin allergy who were diagnosed with infection and had a history of eradication were eligible for inclusion.
Background And Aim: Endoscopic duodenal stenting for patients with malignant gastric outlet obstruction (GOO) has been widespread; however, clinical trials evaluating the structures of duodenal stents are lacking. Thus, we aimed to investigate the clinical outcomes of a highly flexible duodenal stent for GOO patients.
Methods: A prospective study of duodenal stenting for GOO patients from five hospitals between August 2017 and August 2018 was performed.
A 50-year-old woman with stage IV lung adenocarcinoma received seven cycles of pembrolizumab as third-line chemotherapy. Following the failure of pembrolizumab, she commenced fourth-line chemotherapy of docetaxel and ramucirumab. The patient complained of epigastric pain and a computed tomography (CT) scan revealed oedema-like thickening of the gallbladder wall, dilation of the bile ducts from the common to the intrahepatic bile ducts, and thickening of the common bile duct wall without any visible obstructions.
View Article and Find Full Text PDF